Inari Medical (NARI)
(Real Time Quote from BATS)
$43.30 USD
+0.13 (0.30%)
Updated Sep 24, 2024 12:30 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Income Statements
Fiscal Year end for Inari Medical, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 494 | 383 | 277 | 140 | 51 |
Cost Of Goods | 59 | 45 | 25 | 13 | 6 |
Gross Profit | 435 | 339 | 252 | 127 | 45 |
Selling & Adminstrative & Depr. & Amort Expenses | 449 | 367 | 241 | 108 | 44 |
Income After Depreciation & Amortization | -14 | -28 | 11 | 18 | 1 |
Non-Operating Income | 18 | 2 | 0 | -4 | -1 |
Interest Expense | 0 | 0 | 0 | 1 | 1 |
Pretax Income | 4 | -26 | 11 | 14 | -1 |
Income Taxes | 6 | 3 | 1 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -2 | -29 | 10 | 14 | -1 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -2 | -29 | 10 | 14 | -1 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -17 | -21 | 15 | 20 | 2 |
Depreciation & Amortization (Cash Flow) | -3 | 7 | 4 | 2 | 1 |
Income After Depreciation & Amortization | -14 | -28 | 11 | 18 | 1 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 56.77 | 52.84 | 55.59 | 51.56 | NA |
Diluted EPS Before Non-Recurring Items | 0.13 | -0.55 | 0.18 | 0.27 | NA |
Diluted Net EPS (GAAP) | -0.03 | -0.55 | 0.18 | 0.27 | NA |
Fiscal Year end for Inari Medical, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 145.82 | 143.19 | 132.09 | 126.37 | 119.01 |
Cost Of Goods | 19.99 | 18.89 | 17.01 | 14.48 | 13.84 |
Gross Profit | 125.83 | 124.30 | 115.09 | 111.89 | 105.16 |
SG&A, R&D, and Dept/Amort Expenses | 148.28 | 141.48 | 124.38 | 109.77 | 106.68 |
Income After SG&A, R&D, and Dept/Amort Expenses | -22.45 | -17.18 | -9.29 | 2.12 | -1.52 |
Non-Operating Income | 1.10 | 1.17 | 6.19 | 3.52 | 4.58 |
Interest Expense | 0.08 | 0.08 | 0.07 | 0.04 | 0.04 |
Pretax Income | -21.42 | -16.09 | -3.17 | 5.59 | 3.02 |
Income Taxes | 9.93 | 8.12 | 1.49 | 2.43 | 0.94 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -31.35 | -24.20 | -4.67 | 3.16 | 2.09 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -31.35 | -24.20 | -4.67 | 3.16 | 2.09 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 58.14 | 57.94 | 57.64 | 58.59 | 58.50 |
Diluted EPS Before Non-Recurring Items | -0.41 | -0.26 | 0.05 | 0.05 | 0.04 |
Diluted Net EPS (GAAP) | -0.54 | -0.42 | -0.08 | 0.05 | 0.04 |